Concord Medical

Concord Medical Hospital Management Group Co., Ltd. (hereinafter referred to as "Concord Medical" or "the Group") is a subsidiary of Concord Medical Services Holdings Limited. The Group has long been committed to investing in and operating tumor imaging diagnosis and radiotherapy centers nationwide, and has gradually developed into a national hospital management group capable of providing high-quality medical services. Currently, it has formed a national network of independent oncology medical institutions featuring high-end tertiary tumor specialty hospitals and proton therapy centers as the core, covered by secondary tumor specialty hospitals, outpatient departments, independent imaging centers, and cooperative centers, with proton therapy as a distinctive feature. At present, shareholders of Concord Medical include several well-known investment institutions such as CICC Capital, Gopher Asset, and CITIC Capital, who will jointly support the future development of Concord Medical. Concord Medical Services Holdings Limited (hereinafter referred to as "Concord Medical" or "the Company") (NYSE: CCM) was recommended jointly by J.P. Morgan, Morgan Stanley, and CICC, and was listed on the New York Stock Exchange in 2009 as a holding company primarily engaged in medical services. Founded in 1997, Concord Medical is a professional medical services company whose main business is to provide third-party tumor imaging diagnosis and radiotherapy services, as well as to build and operate independent oncology outpatient departments, independent imaging centers, proton centers, and tumor specialty hospitals. In 2015, the Company signed a comprehensive strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, ranked in the United States. The two parties will conduct in-depth cooperation in multiple areas, including diagnosis and treatment technology, radiotherapy quality control, medical processes, operation management, brand use in Singapore and Mainland China, as well as proton center operation and training, jointly building an international oncology hospital based on multidisciplinary diagnosis and treatment mode, oriented by clinical research, and with subspecialty expertise, to optimize patient experience and improve the level of tumor diagnosis and treatment in China. Core values: humanity as the foundation, medical excellence as the priority. The business includes three major sectors: 1. Medical imaging and radiotherapy centers, namely domestic medical imaging diagnosis and radiation oncology treatment centers managed on platforms of Medical Star and Shenzhen Aohua, located in 21 cities; 2. Chain secondary hospitals and independent medical institutions. Currently, secondary hospitals under the brand "Concord Medical" are operated and under construction in multiple cities, providing patients with imaging diagnosis and radiotherapy/chemotherapy services under the internationally most stringent quality control system; 3. In Beijing, Shanghai, and Guangzhou, the Company operates and manages multidisciplinary diagnosis and treatment (MDT) high-end oncology hospitals including proton therapy, as well as Singapore Concord International Cancer Hospital. Concord Medical Services Holdings Limited will take the construction of the most trusted service and management platform for tumor diagnosis and treatment specialty hospitals as its long-term vision, emphasize corporate social responsibility, and actively promote the development of the industry.